血清CEA、NSE、Cyfra21-1水平与肺癌分期、近期疗效及生存时间的相关性研究  

A study of correlation between serum CEA,NSE,Cyfra21-1 levels and stage,response and survival in patients with lung cancer

作　　者：王宏羽[1] 屈风莲[1] 张湘茹[1] 周云飞[1] 储大同[1] 孙燕[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《癌症进展》2004年第4期295-298,共4页Oncology Progress

摘　　要：目的　研究肺癌患者血清CEA、NSE、Cyfra2 1 1水平与肺癌分期、近期疗效及生存时间的关系。方法　确诊为肺癌的患者 ,化疗前、后常规检查血清CEA、NSE、Cyfra2 1 1,评估其变化 ,所有入组患者随访 5年。结果　 96例肺癌患者中 ,血清肿瘤标志物增高者为 6 6 6 7% (6 4 96 ) ,其中SCLC为 6 4 71% (2 2 34) ;NSCLC为 6 7 74 % (4 2 6 2 ) ;SCLC患者血清CEA、NSE、Cy fra2 1 1增高的发生率分别为 8 82 % (3 34)、 5 5 88% (19 34)及 2 9 4 1% (10 34) ;NSCLC患者分别为 35 4 8% (2 2 6 2 )、 19 35 % (12 6 2 )及 4 3 6 5 % (2 7 6 2 ) ;其中肺腺癌分别为 4 5 2 4 % (19 4 2 )、 11 90 % (5 4 2 )及 38 10 % (16 4 2 ) ,肺鳞癌分别为 18 75 % (3 16 )、 31 2 5 % (5 16 )及5 6 2 5 % (9 16 ) ;SCLC局限期分别为 0 %、 15 79% (3 19)及 0 % ,广泛期分别为 10 0 % (3 3)、84 2 1% (16 19)及 10 0 % (10 10 ) ;ⅢB 期NSCLC分别为 9 0 9% (2 2 2 )、 0 %及 11 11% (3 2 7) ;Ⅳ期分别为 90 91% (2 0 2 2 )、 10 0 % (14 14 )及 88 89% (2 4 2 7) ;化疗后 ,SCLC血清NSE降至正常者为 94 74 % (18 19) ,NSCLC血清CEA、Cyfra2 1 1降低或降至正常者分别为 6 8 18% (15 2 2 )及 92 6 % (2Objective To study the correlation between serum CEA、NSE and Cyfra21-1 levels and stage、response and survival in patients with lung cancer.Methods 96 lung cancer patients were examined serum CEA,NSE and Cyfra21-1 levels before and after chemotherapy,and were followed up for 5 years.Results Higher serum CEA,NSE and Cyfra21-1 levels were 8.82%(3/34),55.88%(19/34)and 29.41%(10/34)in SCLC respectively;35.48%(22/62),19.35%(12/62)and 43.65%(27/62)in NSCLC respectively;45.24%(19/42),14.29%(6/42)and 38.10%(16/42)in adenocarcinoma respectively;18.75% (3/16) ,31.25%(5/16)and 56.25%(9/16)in squamous cell carcinoma respectively;LD stage were 0%,15.79%(3/19)and 0%in SCLC respectively;ED stage were 100%(3/3),84.21%(16/19)and 100%(10/10);stage ⅢB were 9.09%(2/22),0%and 11.11%(3/27)in NSCLC respectively;stageⅣwere 90.91%(20/22),100%(12/12)and 88.89%(24/27)respectively.Higher tumor makers serum were 64.71%(22/34)in SCLC patients;and 67.74%(42/62)in NSCLC;after chemotherapy,high serum NSE that were reduced to normal were 94.74%(18/19)in SCLC,CEA and Cyfra21-1 reduced or reduced to normal were 68.18%(15/22)and 92.6%(25/27)respectively;the overall survival was 18.18 months in SCLC;16.36 months in NSCLC;Conclusion Higher serum CEA、NSE、Cyfra21-1 levels were related to stage,response and survival in patients with lung cancer,they were found in advanced stage and reduced after chemotherapy.The prognosis was poor and survival was shorter in patients with high serum tumor markers.

关 键 词：肺癌 CEA NSE CYFRA21-1 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]